Interní Med. 2002; 4(1): 29-32

Současné trendy trombolytické terapie u akutních koronárních syndromů

MUDr. Jana Gandalovičová
II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gandalovičová J. Současné trendy trombolytické terapie u akutních koronárních syndromů. Interní Med. 2002;4(1):29-32.

V článku je popsán současný stav trombolytické léčby včetně indikací a kontraindikací, jsou diskutovány její limitace a výběr trombolytika. Jsou představeny nové aktivátory plazminogenu a jejich vlastnosti. V závěru jsou uvedeny výsledky nedávno uveřejněných studií GUSTO V a ASSENT - 3.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Assessment of the Safety and Efficacy of a New Trombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-722.
    2. Assessment of the Safety and Efficacy of a New Trombolytic (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-613.
    3. Bode C, Smalling RW, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plazminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plazminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94: 891-898. Go to original source... Go to PubMed...
    4. Boersma E, Maas ECP. Early thrombolytic treatment in acute myocardila infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-775. Go to original source... Go to PubMed...
    5. Cannon CP, Gibson M, et al. TNK-tissue plazminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998; 98: 2805-2814. Go to original source... Go to PubMed...
    6. Collen D, Bounameaux H, et al. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plazminogen activator in patients with acute myocardial infarction. Circulation 1986; 73: 511-517. Go to original source... Go to PubMed...
    7. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322. Go to original source...
    8. Goldman L, Bennett JC. Cecil Textbook of Medicine, WB Saunders Company 2000: 304-312.
    9. The Global Use of Strategies to Open Occluded Arteries (GUSTO-III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-1123. Go to original source... Go to PubMed...
    10. The GUSTO Angiographic Investigators. The effects of tissue plazminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622. Go to original source... Go to PubMed...
    11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682. Go to original source... Go to PubMed...
    12. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-1914. Go to original source... Go to PubMed...
    13. ISIS-3 (Third Intenational Study of Infarct Survival) Collaborative Group: A randomized comparison of streptokinase versus tissue plazminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone in 41,299 cases of suspected acute myocardial infarction: ISIS-3. Lancet 1992; 339: 753-770.
    14. The International Study Group. In hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin.Lancet 1990; 336: 71-75. Go to original source...
    15. Mahaffey KW, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol 1997; 30: 1606-1610. Go to original source... Go to PubMed...
    16. Ryan TJ, Antman EM, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on Management of Acute Myocardial Infarction). Circulation 1999; 100: 1016-1030. Go to original source... Go to PubMed...
    17. Tebbe U, et al. for the COMPASS Investigators: Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J AM Coll Cardiol 1998; 31: 487-493. Go to original source... Go to PubMed...
    18. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97: 211-218. Go to original source... Go to PubMed...
    19. Vorchheimer DA. Current state of thrombolytic therapy. Current Cardiol Rep 1999, 1: 212-220. Go to original source... Go to PubMed...
    20. Vorchheimer DA, Baruch L, et al. Does the presence or absence of chest pain at initiation of thrombolysis in acute myocardial infarction affect outcome? J Am Coll Cardiol 1996, 27: 389A. Go to original source...
    21. White HD, Van de Werf FJJ. Thrombolysis for acute myocardial infarction. Circulation 1998; 97: 1632-1646. Go to original source... Go to PubMed...
    22. Wu K, Zerhouni EA, et al. Prognostic significance of microvascular obsrtuction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765-772. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.